Individuals Coming Off Anti-Obesity Jabs Gain Back Pounds Far More Rapidly Than Dieters

A recent study reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who stop traditional lifestyle plans.

Research printed in a prominent medical journal shows that while obese people can lose a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month upon discontinuation.

"Individuals purchasing these medications need to be cognizant of the potential of quick rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.

This pace of recovery suggests a reversion to original mass within about 18 months.

Comparing Therapies

The research, which looked at dozens of studies involving thousands of participants, compared the effects of the injectable medications with conventional dieting.

Scientists emphasize that individuals who lose weight through lifestyle changes alone typically see a more gradual creep back—perhaps 0.1 kg a month—once they finish.

Understanding the Fast Rebound

Nutrition scientists suggest the mechanism of the drugs explains the accelerated rebound.

The injections mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.

"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to produce less of its own natural hormone, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this hormone supplement results in hunger is unsuppressed, making binge eating far more likely."

An Ongoing Issue?

Medical guidelines advise the jabs for people with obesity-related health risks, alongside prescribed diet and exercise modifications.

Many experts say that, due to the likelihood of relapse, the treatment should be considered long-term.

This view is echoed by pharmaceutical companies, who say that the results "emphasize the persistent nature of obesity," akin to managing conditions like diabetes.

User Experiences

Users who have come off the medication describe a sudden resurgence of cravings.

"It felt as if a trigger activating and I was suddenly extremely hungry," recalled a patient.

This challenge is worsened if users have not established sustainable lifestyle or habit modifications during therapy.

Significant Adoption

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.

• Use is greater among females than males.
• The middle-aged age group shows the greatest usage rates.
• Many obtain the drugs through private prescriptions rather than the NHS.

Ultimately, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and long-term success relies on ongoing lifestyle changes.